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Abstract
Background: There are limited data on the characterization of medication-related visits (MRVs) to the emergency
department (ED) in pediatric patients in Italy. We have estimated the frequency, severity, and classification of MRVs
to the ED in pediatric patients.
Methods: We retrospectively analyzed data for children seeking medical evaluation for a MRV over an 8 years
period. A medication-related ED visit was identified by using a random pharmacist assessment, emergency
physician assessment, and in case of conflicting events, by a third investigators random assessment.
Results: In this study, regarding a single tertiary center in Italy, on a total of 147,643 patients from 0 to
14 years old, 497 medication-related visits were found, 54% of which occurred in children from 0 to 2 years
of age. Severity was classified as mild in 21.6% of cases, moderate in 67.2% of cases, and severe in 11.2% of
cases. The most common events were related to drug use without indication (51%), adverse drug reactions
(30.3%), supratherapeutic dosage (13.2%) and improper drug selection (4.5%).
The medication classes most frequently implicated in an ADE were anti-infective drugs for systemic use (28.
9%), central nervous system agents (22.3%) and respiratory system drugs (10.8%).
The most common symptom manifestations were dermatologic conditions (46.1%), general disorder and
administration site conditions (29.7%) and gastrointestinal symptoms (16.0%).
Conclusions: To our knowledge, this is the first study in Italy evaluating the epidemiologic characteristics of MRVs
confirming a significant cause of healthcare contact resulting in ED visits and hospital admissions with associated
resource utilization. Our results suggests further future prospective, large-sample sized, and multicenter research is
necessary to better understand the impact of MRVs and to develop strategies to provide care plans and monitor
patients to prevent medication-related visits.
Trial registration: Not applicable.
Keywords: Medication related events, Medication-related event visits, Medication-related visit, Adverse drug events,
Adverse drug reactions, Medication error, Emergency department
* Correspondence: cristiano.rosafio@gmail.com
1Pediatric Unit, Post Graduate School of Pediatrics, University of Modena and
Reggio Emilia, Viale del Pozzo, 71, 41124 Modena, Italy
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Rosafio et al. Italian Journal of Pediatrics  (2017) 43:55 
DOI 10.1186/s13052-017-0375-7
Background
Medication related events (MREs) are disadvantageous
occurences, mostly preventable, related to use of a
drug [1, 2].
It has been estimated that MREs are a significant
problem in term of impact of consultations in Emer-
gency Department (ED) and hospital admission in
pediatric patients, contributing to overall pressures on
health care system [3–5]. Previous studies focused on
adverse drug events (ADEs) involved different method-
ologies and a spectrum of different inclusion criteria,
ranged from studies of narrowly defined adverse drug re-
actions (ADRs) to more broadly defined medication-
related events” [4, 6–44].
The Italian active pharmacovigilance project ‘Monitor-
ing of the adverse effects in pediatric population’
(MEAP), aimed to assess pediatric ADRs, provided a
valid strategy to identify previously unknown ADRs, re-
duce underreporting and increase awareness in pediatric
clinical practice [45]. This project however is focused ex-
clusively on pediatric ADRs, therefore little is known
about pediatric ADEs [46–48] and no study has previ-
ously explored pediatric MREs, in Italy.
Thus there remains a significant knowledge gap in our
understanding the magnitude of MREs in pediatric
population. The purpose of this report is to explore
retrospectively the phenomenon of MREs in pediatric
patients that result in ED visit.
Methods
We performed a retrospective cohort analysis reviewing
all available electronic ED charts, collecting data from
visits by children 0 to 14 years from 2007 to 2014 pre-
senting to the ED of a single tertiary center, Azienda
Ospedaliero-Universitaria Policlinico of Modena.
Independent investigators were full trained in prede-
fined data-extraction criteria and the classification of
Medication-Related Event visits (MRV) using a predefined
approach [18, 39] Cases were randomly assigned. In case
of ambiguous or conflicting events, a third investigators
resolved the conflicts by discussing with the reviewers to
achieve consensus [49].
Data were recorded anonymously on computerized ab-
straction forms (Microsoft Access 2011, Microsoft
Corporation, Redmond, WA).
An ED visit was considered medication-related if the
presentation was unequivocally related to the presenting
chief concern and codified into 1 of 8 predefined cat-
egories, Table 1: ADR, drug interaction, improper drug
selection, untreated indication, sub therapeutic dosage,
supra-therapeutic dosage, non-adherence, and drug use
without indication [50–53].
Both Naranjo Scale and World Health Organization
(WHO) algorithm was used to determine causality [54, 55].
We considered an adverse drug related event as
present if the WHO algorithm was deemed “certain” or
“probable” or the Naranjo Scale was deemed “definite”
or “probable” [18].
MRV severity was ranked as fatal, severe (life threaten-
ing or resulting in permanent disability), moderate (la-
boratory abnormality or symptom requiring treatment/
hospitalization or resulting in non-permanent disability)
and mild (laboratory abnormality or symptom not re-
quiring treatment) [14, 18]. Potential MRV was included
in our study. A potential MRV was defined as incidents
with potential for injury related to a drug [7]. If treat-
ment was started in order to prevent medical conse-
quences we considered it as a potential MRV. We
decided to evaluate potential MRV on the assumption
that the causes of potential MRV are similar to the
causes of true MRV [7].
We excluded drugs used for intentional self-harm and
event caused by illicit drugs, nicotine, ethanol, nutri-
tional supplements, complementary and alternative
medication and assault by poisoning. Furthermore, we
excluded ED visits that were made by the same patient.
Table 1 Categorization of Drug Related Problems [49]
ADR Any noxious, unintended, or undesired effect of a drug that occurs at doses used in humans for prophylaxis, diagnosis,
or treatment. These will include all reactions when drugs are used at appropriate doses and may include abnormal
laboratory values.
Untreated indication Any noxious, unintended, or undesired effect resulting from the failure to treat a known indication
Improper drug selection Any noxious, unintended, or undesired effect due to the use of a drug not optimal in the treatment of a confirmed
indication
Subtherapeutic dosage Anynoxious,unintended,orundesiredeffectcausedbyfailuretoreceive sufficient drug dosage or duration for a given
indication or patient
Supratherapeutic dosage Any noxious, unintended, or undesired effect caused by excessive drug dose or duration for a given indication or
patient
Nonadherence Any noxious, unintended, or undesired effect caused by failure to receive a drug as prescribed by a health care
provider
Drug use without indication Any noxious, unintended, or undesired effect caused by the use of a drug for which there is no clear indication
Drug interaction Any noxious, unintended, or undesired effect caused by the coadministration of 2 or more drugs
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Narrative summaries, clinical testing, and physician’s
diagnoses from MRVs reports were coded according to
Medical Dictionary for regulatory Activities (MedDRA)
terminology and System Organ Class (SOC) list [56].
Medication involved in each event was classified accord-
ing to anatomical therapeutic classification code (ATC).
The study was performed on the basis of the rules of
Ethical Committee.
Descriptive analysis (mean and standard deviation for
continuous data, absolute frequency and percentage for
categorical data) was performed with STATISTICA™
software (StatSoft Inc., Tulsa, OK, USA).
The primary outcome (Number of MRVs, Severity of
True MRVs and Classification) of emergency department
visits that were drug-related is reported as a percentage
with 95% confidence interval (CI).
Results
Over the 8-year period a total of 147.643 patients pre-
sented to the ED, with a mean (SD) of 18.455 (805.7)
visits per year.
A total of 497 MRVs (0.34%, 95% CI 0.31% to 0.37%)
were identified with the highest proportion of visits by
children 0–2 years old who accounted for 54% of visits.
Table 2 Demographic findings of patients (n = 497)
Characteristics n(%, 95% CI)
Age, mean (SD, CI 95%) 3.2(2.9, 95% CI 0.31% to 0.37%))
age category
0–2 y 269 (54)
2–6 y 168 (33)
6–14 60 (13)
Gender
girl 225 (45)
Boy 272 (55)
Classification of MRVs (n = 497)
Drug Use Without Indication 257(51)
ADR 152(30.3)
Supratherapeutic Dosage 66(13.2)
Improper Drug Selection 22(4.5)
True MRVs 232 (46.5)
ADR 152(65.5)
Medication related-ADRs 87(37.5)
Vaccination Related-ADRs 65(28)
Drug Use Without Indication 46(19.8)
Supratherapeutic Dosage 26(11.2)
Improper Drug Selection 8(3.5)
Potential MRVs 265 (53.5)
Drug Use Without Indication 211 (79.6)
Supratherapeutic Dosage 40(15.1)
Improper Drug Selection 14(5.3)
Degree of severity
True MRVs
(n = 232)
Medication related-ADRs
(n = 87)
VACCINES
(n = 65)
Mild 50 (21.6, 95% CI 7.5% to 16.0%) 16 (18.4) 12 (18.5)
Moderate 156 (67.295% CI 60.7% to 73.2%) 66 (75.8) 52 (80)
Severe 26 (11.2, 95% CI 16.4% to 27.4%) 5 (5.8) 1 (1.5)
Outcome
Hospitalization 34(6.8)
Death -
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Drug use without indication-related visit accounted for
257 cases (51%) followed by ADR-related visits 152 cases
(30,3%), supratherapeutic dosage-related visit 66 cases
(13.2%) and improper drug selection-related visit 22
cases (4.5%) Table 2.
Potential MRVs was found in 265 cases (53.5%) while
a true MRV in 232 cases (46.5%).
Among true MRVs the most common events were re-
lated to ADRs 152(65.5%), followed by drug use without
indication 46(19.8%), supratherapeutic dosage 26(11.2%),
and improper drug selection 8(3.5%) while among po-
tential MRVs the most common events were related to
drug use without indication 211(79.6%), followed by
supratherapeutic dosage 40(15.1%) and improper drug
selection 14(5.3%).
Medication-related ADRs accounted for 87 cases
(37.5%) while Vaccination-related ADRs accounted for
65 cases (28%).
Severity classification was for True MRVs, mild in 50
cases (21.6%, 95% CI 16.4% to 27.4%), moderate in 156
cases (67.2%, 95% CI 60.7% to 73.2%), severe in 26 cases
(11.2%, 95%CI 7.5% to 16.0%), for medication-related
ADRs, severe in 5 cases (5.8%), moderate in 66 cases
(75.8%), mild in 16 cases (18.4%) and for Vaccine-related
ADRs mild in 12 cases(18.5%), moderate in 52 cases(80%)
and severe in 1 case (1.5%).
Table 3 Medication Associated To MRVs
ATC classes
Total MRVs
(n = 497)
n(%)
True MRVs
(n = 232)
n(%)
Potential MRVs
(n = 265)
n(%)
Medication-related ADRs
(n = 87)
n(%)
Antiinfectives for systemic use 144 (28.9) 129 (55.6) 15 (5.6) 52 (59.7)
Vaccines 65 (45.1) 65 (50.3) - - - -
Beta-Lactam Antibacterials 59 (40.9) 47 (36.4) 12 (80.0) 43 (82.6)
Macrolides, Lincosamides and Streptogramins 15 (10.4) 12 (9.3) 3 (20) 5 (9.6)
Nervous System 111 (22.3) 40a (17.2) 71 (26.7) 7 (8.0)
Paracetamol 34 (30.6) 13 (32.5) 21 (29.5) 1 (14.2)
Psycholepticts 29 (26.1) 9 (22.5) 20 (28.1) - -
Antidepressants 17 (15.3) 7 (17.5) 10 (14.0) - -
Antiepileptics 14 (12.6) 5 (12.5) 9 (12.6) 3 (42.8)
Opioids 5 (4.5) 1 (2.5) 4 (5.6) 1 (14.2)
Respiratory System 54 (10.8) 14b (6) 40 (15 6 (6.8)
Adrenergics, Inhalants 18 (33.3) 8 (57.1) 10 (25) 3 (50)
Antihistamines for Systemic Use 17 (31.4) 3 (21.4) 14 (35) - -
Cough and Cold Preparations 10 (18.5) 2 (14.2) 8 (20) 2 (33.3
Alimentary Tract and Metabolism 52 (10.4) 15c (6.4) 37 (13.9 7 (8.0)
Drugs for Functional Gastrointestinal Disorders (domperidone,
metoclopramide, cimetropium bromide)
15 (28.8) 4 (26.6) 11 (29.7) 2 (28.5)
Stomatological Preparations 10 (19.2) 1 (6.6) 9 (24.3) - -
Blood Glucose Lowering Drugs, Excl. Insulins 7 (13.4) 4 (26.6) 3 (8.1) - -
Vitamins 6 (11.5) 2 (13.3) 4 (10.8) 1 (14.2)
Drugs for Acid Related Disorders 4 (7.6) - - 411 (36.3) - -
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents 4 (7.6) 1 (6.6) 3 (8.1) 1 (14.2)
Drugs for Constipation 3 (5.7) 1 (6.6) 2 (5.4) 1 (14.2)
Antiemetics and Antinauseants 2 (3.8) 2 (13.3) - - 2 (28.5)
Musculo-Skeletal System 36 (7.2) 14 (6) 22 (8.3) 11 (12.6)
NSAIDs (ketoprofen, ibuprofen) 31 (86.1) 14 (100) 17 (77.2) 11 (100)
a18(45) cases were drug use without indication-related event, 10(25) cases were supratherapeutic dosage-related event, 5(12.5) cases were improper drug
selection-related event;
b5(35.7) cases were drug use without indication-related event, 2(14.2) cases were supratherapeutic dosage-related event, 1(7.1) cases were improper drug
selection-related event;
c5(33.3) cases were drug use without indication-related event, 3(20) cases were supratherapeutic dosage-related event;
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The medication classes most frequently implicated in the
total MRVs were anti-infective drugs for systemic use
(28.9%, 95% CI 25.0% to 33.1%), central nervous system
agents (22.3%, 95% CI 18.7% to 26.2%) and respiratory sys-
tem drugs (10.8%, 95% CI 8.3% to 13.9%) Table 3.
Among MRVs related to anti-infective for systemic use
45.1% were the result of a vaccine, 40.9% were the result
of a beta-lactam antibacterial and 10.4% of a macrolides.
Central nervous system agents-related events were most
often linked to use of paracetamol (30.6%), psycholepticts
(26.1%), antidepressants (15.3%) and antiepileptic drugs
(12.6%). The majority of MREs involving respiratory sys-
tem agents were associated with adrenergic inhalants
(33.3%) and antihistamines for systemic use (31.4%).
Anti-infective drugs for systemic use (55.6%) and
Nervous system agents (17.2%) are the major
medication classes involved in true MRVs with respect-
ively Vaccines (50.3%), beta-lactam antibacterials
(36.4%), paracetamol (32.5%) and psycoleptics (22.5%).
The major categories of medications involved in
medication-related ADRs included anti-infective for
systemic use (59.7%) with an 82.6% of beta-lactam anti-
bacterial involved while nervous system agents are the
most common drug classes involved in MRVs not clas-
sifiable as an ADR. Table 4.
Dermatologic conditions were the most common true
MRVs and Medication-Related ADRs manifestation,
present respectively in 46.1% and in 88.5% of cases of
true MRVs followed by general disorder and administra-
tion site conditions in 29.7% of cases and by gastrointes-
tinal symptoms in 16.0% of cases of medication related
ADRs. Table 5.
General disorders and administration site conditions
were the most common Vaccination-Related ADR mani-
festation, present in 83.0% of cases followed by dermato-
logic conditions in 43.0% of cases. Table 5.
In 41.5% of cases the type of vaccines was not re-
ported, severity was classified mostly moderate (80% of
cases) and type of reaction was manly systemic. Among
the rest of available type of vaccines, Hexavalent (13.8%),
DTaP-MMR(12%) and MMR(7.6%) were predominantly
associated with an MRV with a mild-moderate severity
classification. Table 6.
Discussion
Definition and classification of ADEs was not stan-
dardized across different studies so we decided to
study MREs following the more comprehensive and
reproducible definition of Hepler and Strand [50].
This taxonomy provides a more accurate and inclu-
sive evaluation of drug-related event and a meaningful
characterization of MRVs in ED. In our analysis
MRVs accounted for 0.34% of the ED visits appearing
similar to the range of 0.5% to 3.3% found in previ-
ous studies [32, 52, 57–60].
To our knowledge the extent of MRVs presenting to
ED, exclusively among the pediatric population, has not
been previously studied in Italy.
Comparisons with the other Italian studies is challenging
since there are limited researches that have investigated
pediatric ADEs presenting to ED. Capuano et al. reported
only 3(0.41%) patients aged 0–19 years old presenting an
ADE [46], Trifirò et al. reported 39(1.9%) patients aged 0–
19 years old [48] and Raschetti et al. reported 10(3.8%) pa-
tients aged 0–20 years old [47]. Considering these studies,
the sample size and the age range limit the possibilities for
comparison.
More than two-thirds of true MRVs were identified as
being moderate and mild as most commonly described
in previous studies [32, 44, 52, 61, 62].
The rate of hospitalization (34 cases, 6.8%) was a
slightly greater than reported in the literature (0.16–
Table 4 Medication associated to MRVS not related to ADRs
ATC classes True
Drug use
without
indication
n = 46
n(%)
Potential Drug use
without indication
n = 211
n(%)
True
Supratherapeutic
dosage
n = 26
n(%)
Potential
Supratherapeutic
dosage
n = 40
n(%)
True Improper
drug selection
n = 8
n(%)
Potential Improper
drug selection
n = 14
n(%)
Nervous System 18(39.1) 52(24.6) 10(38.4) 12(30) 5(62.5) 6(42.8)
Cardiac 5(10.8) 27(12.8) - - 1(12.5) -
Respiratory System 5(10.8) 27(12.8) 2(7.7) 9(22.5) 1(12.5) 4(28.5)
Alimentary Tract and
Metabolism
5(10.8) 24(11.3) 3(11.5) 9(22.5) - 4(28.5)
Musculo-Skeletal System 3(6.5) 22(10.4) - - - -
Antiinfectives For
Systemic Use
3(6.5) 6(2.8) 9(34.6) 9(22.5) - -
Genito Urinary System
and Sex Hormones)
1(2.1) 22(10.4) - - - -
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4.3%) [63]. This increase should be interpreted in the
light of the need to a prolonged period of observation.
As previously reported [52, 58, 64, 65] drug use without
indication related visits and ADRs are the most common
MRVs. These most commonly occurred after intake of
anti-infective for systemic use agents, nervous system
drugs and respiratory system agents causing dermatologic
manifestation followed by general disorders, administra-
tion site conditions and gastrointestinal manifestation.
Among medication related-ADRs dermatological mani-
festation after beta-lactam antibacterial use is the most
common disorder which is consistent with the findings of
the major national ADRs overview conducted in Italy
from 2001 to 2012, collecting data from the Italian Phar-
macovigilance Network database [45, 66].
Consistency of our data could be explained by a partial
overlapping of the nature of pediatric population across
the countries. This could probably be an echo of the
scenery of disease prevalence and correlated medication
use in children.
The results of research in adults could not be
generalizable to children [67].
The European Regulation on Medicines for Pediatric
use came into force on 26 January 2007 increased pre-
marketing drug safety but efforts should take place at all
levels to improve drug safety in a ‘real-life’ setting [66].
Kozer et al. [68] proposed some strategies that have
the potential to reduce pediatric drug-related problems
focusing on a ‘system approach’ view in which a medical
error is a system error. PROTECT initiative [69], devel-
oped by The Centers for Disease Control and Preven-
tion, delineated the key priorities for early action aimed
to reduce medication errors.
There are several limitations in our study. First, the
retrospective design of this study could underestimate
the true incidence of MRVs. We consider the assessment
of an experienced pharmacist and an independent phys-
ician both trained in recognition and resolution of MRVs
to increase likelihood that all medication-related causes
of an ED visit were identified and minimize potential
misclassification.
Although we used an independent adjudication, process
bias may have occurred in the categorization of the case
summaries. Furthermore, retrospective analysis of data is
limited by the impossibility to obtain additional informa-
tion on the type of drug reaction.
Second, physicians may not have recognized a symp-
tom as related to a medication; patient’s report could
Table 5 Symptoms of pediatric MRVs
Symptoms
True MRVs
n(%)
Medication
related-
ADRs
n(%)
Vaccination Related-
ADRs n(%)
Drug use without
indication
n(%)
Supratherapeutic
dosage
n(%)
Improper drug
selection
n(%)
Skin and subcutaneous tissue disorders 107 (46.1) 77 (88.5) 28 (43.0) 1(2.1) 1(3.8) -
General disorders and administration
site conditions
69 (29.7) 9 (10.3) 54 (83.0) 3(6.5) 3(11.5) -
Gastrointestinal disorders 56 (24.1) 14 (16.0) 8 (12.3) 18(39.1) 14(53.8) 2(25)
Nervous system disorders 30 (12.9) 4 (4.6) 1 (1.5) 16(34.7) 4(15.3) 5(62.5)
Eye disorders 15 (6.4) 9 (10.3) 2 (3.0) 1(2.1) 1(3.8) 2(25)
Respiratory, thoracic and mediastinal
disorders
15 (6.4) 4 (4.6) 6 (9.2) - 4(15.3) 1(12.5)
Psychiatric disorders 12 (5.1) 2 (2.3) 4 (6.1) 5(10.8) 1(3.8) -
Musculoskeletal and connective tissue
disorders
7 (3.0) 1 (1.1) 3 (4.6) - 2(7.6) 1(12.5)
Table 6 Reactions reported for each type of vaccines (n = 65)
Type of reaction
TYPE n(%) Systemic Local Systemic and Local
Not Reported 27 (41.54) 21 4 2
Hexavalent 9 (13.85) 7 2
DTaP, MMR 8 (12.31) 1 5 2
MMR 5 (7.69) 2 1 2
MMR, MEN C 3 (4.62) 3
DTaP, IPV 3 (4.62) 2 1
HPV 2 (3.08) 2
PCV 2 (3.08) 1 1
PNEUMOVAX 23 2 (3.08) 2
BCG 1 (1.54) 1
Hepa B 1 (1.54) 1
MEN C 1 (1.54) 1
MMR, DTP, IPV 1 (1.54) 1
DTaP difto-tetanus-pertussis vaccine, IPV inactivated antipolio vaccine, Hepa B
Hepatitis B vaccine, Hib Haemophilus Influenzea type B vaccine, MMR measles,
mumps, rubella vaccine, PCV pneumococcal eptavalente conjugate vaccine,
MEN C meningococcal C conjugate vaccine, PNEUMOVAX 23 pneumococcal
vaccine polyvalent, HEXAVALENT DTaP/Hib/IPV/HepB vaccine, BCG bacille
Calmette-Guérin (BCG) vaccine
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have been incomplete or presenting with multiple prob-
lems. So it is possible that some cases were not classified
as a MRV.
Third, conditions with significant impact like medica-
tion nonadherence and the related increased health care
use in children and adolescent who have chronic med-
ical condition were not evaluated [70].
Finally given the retrospective nature of the study
and the involvement of one single hospital, our re-
sults are not necessarily generalizable to the pediatric
ED setting.
Conclusion
MRVs are common medical complications among chil-
dren in our setting and a challenge for the health care
system. Our results are consistent with those from the
current literature. Future prospective, large-sample
sized, and multicenter research should focus in differ-
ent settings on this topic to better understand the
impact of MRV and the real effect of programmed pre-
ventive actions.
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